Vext ScienceVEXTF -3.15%69 EBITDA Margin % is 34.37% as of Mar. 2026, which is 15% above its 10-year median of 29.80. GuruFocus rates VEXTF with a GF Score™ of 69/100 and a GF Value™ of $1.06 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 952 Drug Manufacturers companies, Vext Science ranks better than 58.82% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vext Science's EBITDA for the
three
months ended in Mar. 2026 was $4.18 Mil. Vext Science's Revenue for the
three
months ended in Mar. 2026 was $12.16 Mil. Therefore, Vext Science's EBITDA margin for the quarter that ended in Mar. 2026 was 34.37%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vext Science EBITDA Margin % Related Terms
Vext Science EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vext Science's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vext Science's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (VEXTF) has a EBITDA Margin % of 34.37% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vext Science and its competitors. This is 15% above median its historical median of 29.80. According to the industry distribution chart, Vext Science ranks #392 out of 952 companies in the Drug Manufacturers industry, placing it in the top 41.2%.
Is Vext Science's EBITDA Margin % too high?
Vext Science's current EBITDA Margin % of 34.37% is 15% above median its 10-year median of 29.80. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Vext Science's value of 34.37% is 175.6% above this industry median. Based on the distribution chart, Vext Science ranks #392 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vext Science has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vext Science's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #392 out of 952 companies for EBITDA Margin %. This puts Vext Science in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Vext Science's value of 34.37% is 175.6% above this benchmark. While the company's 10-year median is 29.80 vs. the industry median of 12.47, Vext Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current EBITDA Margin % of 34.37% is 175.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current EBITDA Margin % is 34.37%, which is 15% above median its own 10-year median of 29.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Based on GuruFocus' analysis, Vext Science (VEXTF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.06, compared to a current price of $0.18 — trading 83.2% below its estimated fair value. The current EBITDA Margin % is 34.37%, which is 15% above median its 10-year median of 29.80 and 175.6% above the Drug Manufacturers industry median of 12.47. Vext Science's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vext Science (VEXTF), the current EBITDA Margin % is 34.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (VEXTF) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of $0.18 is trading 83.2% below its estimated GF Value™ of $1.06.
GuruFocus considers Vext Science to be Possible Value Trap.
Key valuation signals for VEXTF:
EBITDA Margin %: 34.37% (15% above median its 10-year median of 29.80)
GF Value™: $1.06 vs. price of $0.18 (83.2% below fair value)
Industry Position: 175.6% above the Drug Manufacturers median (#392 of 952)
No single metric tells the full story. See the VEXTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
69GF Score
Get the complete analysis for VEXTF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VEXTF has been successfully added to your 
